TapImmune (TPIV) In License Agreement with Crucell (CRXL) Nov 5, 2009 09:09AM

TapImmune Inc. (OTCBB: TPIV) announced a license agreement with Crucell N.V. (Nasdaq: CRXL).

Under the license TapImmune may use the proprietary PER.C6(R) cells in its development programs. The PER.C6(R) cell line is ideally suited for the development and large-scale manufacturing of a multitude of biopharmaceuticals. In the use of recombinant vaccines using adenoviral vectors, PER.C6(R) cells do not generate replication competent adenoviruses, making it the state-of-the-art platform for the large-scale production of adenoviral vectors for clinical applications.


Poniard Pharma (PARD) option volume and prices elevated into data Nov 5, 2009 07:16AM

Poniard (Nasdaq: PARD) closed at $7.09. PARD is a biopharmaceutical company focused on development of oncology products. SPEAR Phase three study in small cell lung cancer (SCLC) on PARD's Picoplatin is expected by year end 2009. The study was designed to evaluate picoplatin vs. best supportive care for the treatment of platinum resistant/refractory SCLC. PARD November 7.5 straddle $3.15, December is at $5.95. PARD November option implied volatility is at 272, December is at 296, March is at 198, according to Track Data. Paul Foster


BioCryst (BCRX) Receives Order for 10K Courses of Peramivir from U.S. for H1N1, Worth $22.5M Nov 5, 2009 07:07AM

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) received an initial order for 10,000 courses of intravenous (i.v.) peramivir (600 mg once-daily for five days) with a value of $22.5 million under a newly issued contract with the Department of Health and Human Services (HHS). On November 4, BioCryst shipped the entire order from existing i.v. peramivir inventory to HHS.

"BioCryst is pleased to deliver this initial U.S. Government order for peramivir for use under the Emergency Use Authorization, or EUA, to treat hospitalized adult and pediatric influenza patients who may benefit from peramivir," said Jon P. Stonehouse, President and Chief Executive Officer at BioCryst. "We expect to complete production of approximately 120,000 additional courses of i.v. peramivir by the end of December, and we are prepared to produce more if required to meet orders for the U.S. or other governments. BioCryst has been in contact with a number of governments around the world that are assessing i.v. peramivir for critically ill influenza patients.


BioCryst (BCRX) Jumps Higher After Canceling Conference Appearance Nov 4, 2009 02:14PM

Shares of BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) are flying higher this afternoon after updating on its website that they cancelled today's appearance at an Oppenheimer conference "due to recent developments". Speculators are betting on a takeover or major partnership. Shares are up 7.6% on heavier-than-normal volume.


BioCryst recently received emergency use authorization for the investigational anti-viral drug intravenous peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.


Merriman Curhan Positive On Celldex Therapeutics (CLDX) After Results and Ahead of Events Nov 4, 2009 11:11AM

Merriman Curhan Ford issues comments on Celldex Therapeutics, Inc. (Nasdaq: CLDX) after Q3 results. The firm expect positive incremental catalysts in the near term. "Updated Phase II breast cancer data with CDX-011 (formerly Curagen's CRO-011) will be presented at the San Antonio Breast Cancer Symposium, December 9-13." The firm reiterated their Buy rating and $14-$15 price target.


More FDA

View Older Stories

Nov 4, 2009 09:07AM BioCryst (BCRX) Partner In Japan Files NDA for Peramivir
Nov 4, 2009 08:59AM RXi Pharmaceuticals (RXII) Data to Be Presented at Conference Today
Nov 4, 2009 08:34AM GenVec (GNVC) Up After FDA Grants Orphan Drug Designation for TNFerade
Nov 3, 2009 11:53AM InterMune (ITMN) Higher Following INFORM-1 Trial Data
Nov 2, 2009 11:05AM Human Genome (HGSI) Second Successful Trial Sets Stage For Benlysta Approval
Nov 2, 2009 10:40AM Cardium (CXM) Plans File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL
Nov 2, 2009 09:00AM Hemispherx (HEB) To Widen Program for Chronic Fatigue Syndrome, Provides Update on Ampligen
Nov 2, 2009 08:43AM Dendreon (DNDN) Completes Submission of Amended Biologics License Application for PROVENGE®
Nov 2, 2009 08:42AM Dendreon (DNDN) Completes Submission of Biologics License Application for PROVENGE
Nov 2, 2009 08:19AM GTx (GXTI) Says FDA Identified Two Deficiencies in the Complete Response Letter for Toremifene NDA
Nov 2, 2009 07:25AM Amylin (AMLN) and Takeda Enter Development Agreement for Obesity Treatments
Nov 2, 2009 07:23AM Amylin (AMLN) Announces BYETTA Approved As Stand-Alone Medication
Nov 2, 2009 06:51AM Human Genome (HGSI) and GlaxoSmithKline Announced That BENLYSTA Met the Primary Endpoint in Second Phase 3 Trial
Oct 30, 2009 12:35PM Geron (GERN) Announces Plan to Advance Clinical Development of Stem Cell Product; Will Enable Reinitiation of Phase I Trial
Oct 30, 2009 06:46AM Stereotaxis (STXS) Receives European Approval for Additional Magnetic Irrigated Catheter
Oct 29, 2009 10:12AM MannKind (MNKD) Reports Positive Data From Two Phase 1 Studies
Oct 29, 2009 10:11AM Celldex Therapeutics (CLDX) Announces Positive Results From Phase Studies of CDX-1307
Oct 29, 2009 09:52AM Transcept Pharmaceuticals (TSPT) Smashed After FDA Asks For More Info on Intermezzo
Oct 27, 2009 02:34PM FDA Panel Weighing If Human Genome's (HGSI) Drug Needs More Study
Oct 27, 2009 09:30AM PURE Bioscience (PURE) Hard Surface Disinfectant Effective Against H1NI
Oct 27, 2009 08:03AM Sinovac Biotech (SVA) Receives Third Order For H1NI Vaccine In China
Oct 26, 2009 04:37PM Icagen (ICGN) Senicapoc Fails In Phase IIa Study
Oct 26, 2009 01:58PM GTX Inc (GTXI) November 10 straddle at $4.95 into results
Oct 26, 2009 09:57AM Gilead Sciences (GILD) Announced that Aztreonam for Inhalation to be Reviewed by U.S. FDA
Oct 26, 2009 09:36AM Impax Laboratories (IPXL) Initiates Phase III Trial of IPX066 in Parkinson's
Oct 26, 2009 09:06AM SuperGen (SUPG) Jumps 20% On Collaboration With GlaxoSmithKline (GSK)
Oct 26, 2009 09:00AM Japanese NIH Expanded the Data on Ampligen For Pandemic Flu
Oct 26, 2009 08:24AM Matrixx (MTXX) Shares Tumble as FDA Won't Reverse Position on Zicam
Oct 26, 2009 07:05AM Shire (SHPGY) Gets 5-Year NCE from US FDA for ADHD Treatment VYVANSE
Oct 26, 2009 07:04AM BioCryst (BCRX) Higher After Peramivir Granted Emergency Use Authorization
Oct 23, 2009 10:36AM Elan (ELN) and Biogen (BIIB) Weak On Jump In Tysabri PML Cases
Oct 23, 2009 08:30AM Headlines from Bloomberg, FDA says Human Genome Sciences (HGSI) anthrax treatment may not work
Oct 22, 2009 08:31AM Amgen (AMGN) Lower Despite Q3 Beat As Company Looks To Address Prolia Issues with FDA (Update)
Oct 21, 2009 08:40AM CombinatoRx (CRXX) Reports Positive Efficacy Results From Synavive Trial
Oct 21, 2009 08:35AM King Pharmaceuticals (KG) Receive Complete Reponse Letter from FDA on CorVue
Oct 20, 2009 03:24PM Teva Pharmaceutical (TEVA) Reported Positive Results from MediWond Debrase Trial
Oct 20, 2009 02:09PM Sangamo (SGMO) to Present Top-Line, Statistically Significant Phase 2 Data from ZFP Therapeutic(TM) Program
Oct 20, 2009 08:36AM BioSante (BPAX) Gets Green Light to Continue LibiGel Study
Oct 20, 2009 08:34AM Medco Health (MHS) Plans Head-to-Head Study of Plavix and Effient
Oct 19, 2009 04:36PM Angiotech Pharmaceuticals (ANPI) Receives FDA Letter Regarding 510k Submission of Bio-Seal
Oct 19, 2009 09:34AM Perrigo (PRGO) Says Duac Patent Litigation Dismissed
Oct 19, 2009 09:26AM Rexahn (RNN) Announces Positive Top-Line Results From Phase IIa Study of SerdaxinTM
Oct 19, 2009 08:49AM Immunomedics (IMMU) Awarded 2 Small Business Grants from NIH
Oct 19, 2009 08:47AM Endo Pharmaceuticals (ENDP) Receives Complete Response From FDA On FORTESTA
Oct 19, 2009 08:33AM Johnson & Johnson (JNJ) Subsidiary Centocor Bio Announces Positive Phase III Simponi Results
Oct 19, 2009 08:18AM Amgen (AMGN) Receives Complete Response Letter from FDA For Prolia in Osteoporosis
Oct 19, 2009 07:31AM Talecris Bio (TLCR) Receives FDA Approval for PROLASTIN-C
Oct 19, 2009 07:06AM Human Genome (HGSI) Receives $75M Payment from Novartis AG (NVS) for Zalbin Hep C Treatment
Oct 16, 2009 02:04PM FDA Approves GlakoSmithKline's (GSK) CERVARIX
Oct 16, 2009 01:24PM Merck (MRK) Receives FDA Approval for GARDASIL(R) in Boys and Young Men
View Older Stories